Emmaus Life Sciences Past Earnings Performance
Past criteria checks 0/6
Emmaus Life Sciences has been growing earnings at an average annual rate of 49.8%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 0.01% per year.
Key information
49.8%
Earnings growth rate
55.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -0.01% |
| Return on equity | n/a |
| Net Margin | -17.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Emmaus Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 20 | -3 | 19 | 1 |
| 30 Jun 24 | 20 | -5 | 19 | 1 |
| 31 Mar 24 | 25 | -5 | 21 | 1 |
| 31 Dec 23 | 30 | -4 | 24 | 1 |
| 30 Sep 23 | 28 | -5 | 24 | 2 |
| 30 Jun 23 | 28 | -5 | 25 | 2 |
| 31 Mar 23 | 22 | -13 | 23 | 2 |
| 31 Dec 22 | 18 | -11 | 21 | 2 |
| 30 Sep 22 | 15 | -18 | 19 | 2 |
| 30 Jun 22 | 16 | -20 | 20 | 2 |
| 31 Mar 22 | 19 | -9 | 19 | 3 |
| 31 Dec 21 | 21 | -16 | 19 | 4 |
| 30 Sep 21 | 24 | -9 | 19 | 4 |
| 30 Jun 21 | 24 | -1 | 18 | 4 |
| 31 Mar 21 | 22 | -13 | 19 | 4 |
| 31 Dec 20 | 23 | 1 | 19 | 2 |
| 30 Sep 20 | 24 | 0 | 19 | 2 |
| 30 Jun 20 | 24 | -24 | 21 | 2 |
| 31 Mar 20 | 25 | -32 | 21 | 2 |
| 31 Dec 19 | 23 | -55 | 22 | 2 |
| 30 Sep 19 | 24 | -87 | 23 | 2 |
| 30 Jun 19 | 23 | -54 | 23 | 2 |
| 31 Mar 19 | 20 | -84 | 23 | 2 |
| 31 Dec 18 | 16 | -73 | 22 | 2 |
| 30 Sep 18 | 8 | -37 | 22 | 2 |
| 30 Jun 18 | 4 | -69 | 19 | 2 |
| 31 Mar 18 | 1 | -33 | 18 | 2 |
| 31 Dec 17 | 1 | -33 | 16 | 3 |
| 30 Sep 17 | 1 | -43 | 12 | 3 |
| 30 Jun 17 | 0 | -32 | 12 | 3 |
| 31 Mar 17 | 0 | -23 | 10 | 2 |
| 31 Dec 16 | 0 | -21 | 10 | 2 |
| 30 Sep 16 | 1 | -19 | 10 | 2 |
| 30 Jun 16 | 1 | -16 | 10 | 2 |
| 31 Mar 16 | 1 | -15 | 10 | 2 |
| 31 Dec 15 | 1 | -13 | 11 | 2 |
| 30 Sep 15 | 0 | -11 | 11 | 1 |
| 30 Jun 15 | 1 | -11 | 11 | 1 |
| 31 Mar 15 | 1 | -18 | 13 | 2 |
| 31 Dec 14 | 1 | -22 | 13 | 2 |
| 30 Sep 14 | 0 | -22 | 13 | 2 |
| 30 Jun 14 | 0 | -23 | 13 | 2 |
| 31 Mar 14 | 0 | -18 | 11 | 2 |
| 31 Dec 13 | 0 | -14 | 11 | 2 |
Quality Earnings: EMMA is currently unprofitable.
Growing Profit Margin: EMMA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EMMA is unprofitable, but has reduced losses over the past 5 years at a rate of 49.8% per year.
Accelerating Growth: Unable to compare EMMA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EMMA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: EMMA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.